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ABSTRACT
Atrial septal defect (ASD) is the most common type of common congenital heart disease (CHD) in adults. During the last 
decade, there has been a remarkable change in the treatment strategy of ASD, shifting the therapeutic gold standard from sur-
gery to transcatheter closure, along with refinements and the evolution of device technology. Reports on the outcome of trans-
catheter ASD closure have shown an excellent efficacy as well as a low complication rate. However, the procedural details and/
or outcomes of this procedure may be influenced by several factors including morphologic characteristics of the defect, co-
morbid diseases, as well as individual factors including age and weight of the patient. Because the risk-benefit relationship in 
both the very young and the elderly subsets of the patients has not been clearly defined yet, closure of an ASD with device may 
be potentially subtracted from the treatment option in these patient groups. In this article, we will review the basis for device 
closure in small children and elderly patients with ASD and provide an overview of the frequently encountered problems. 
(Korean Circ J 2011;41:633-638)
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Introduction 
Atrial septal defect (ASD) is a common congenital heart 
disease (CHD) which accounts for 8-10% of all CHD and is 
considered to be the most common type of CHD in adults. 
Among various types of ASD, the ostium secundum defect ex-
ceeds other types in prevalence and is a good candidate for 
device closure. The therapeutic strategy for secundum ASD 
has shown a remarkable change in the last decade because of 
the evolution of device technology, and currently transcathet-
er closure has become the primary treatment option for most 
patients in many centers. The reported outcomes of transca-
theter ASD closure have been excellent with low complication 
rates. On the other hand, this “usually straightforward” pro-
cedure has several influencing factors that play a role in the 
procedural details and/or outcomes, such as morphologic ch-
aracteristics of the defect, co-morbid disease, as well as indi-
vidual factors including age and weight of the patient. Because 
the risk-benefit relationship in both the very young and the 
elderly groups of patients has not been clearly defined yet, clo-
sure of an ASD with device may be potentially subtracted from 
the treatment option in these patient groups. 
Transcatheter Closure of Atrial Septal 
Defect in Small Children
The need of early intervention
Patients with isolated ASD are usually asymptomatic th-
rough infancy and early childhood and the elective surgery 
may be deferred to 2-4 years of age.1) However, it has also been 
well documented that substantial numbers of small children 
are in need of earlier intervention, especially when the disease 
is complicated by chronic lung disease in prematurely-born in-
fants or associated with certain chromosomal anomalies.2)3) 
Nevertheless, the need for early treatment has been recogniz-
ed in small children who are showing rapidly enlarging defects 
to prevent rendering a suitable ASD to an unsuitable ASD 
for device closure.4)5) Some authors advocate that any defect 
larger than 8 mm with evidence of a significant left to right 
shunt should be closed even in very young patients, because 
such a defect will likely never close spontaneously and may 
even get larger.6) Indeed, in a study on the change in size of 
ASD, a significant enlargement of the defect, more than 50% 
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of the initial size, has been detected in 30% of the studied po-
pulation, which suggests that there is a potential for some of 
the defects to outgrow a possible transcatheter closure.7)
Outcomes of early intervention for secundum atrial 
septal defect
Recent articles on surgical treatment of ASD in young and 
symptomatic infants emphasize on benefits of early surgery 
on the grounds of a dramatically improved clinical course.3) 
There has been a study reporting on increased procedural 
time and lower procedural success rate for transcatheter ASD 
closure during their early experience with the Amplatzer sep-
tal occluder (ASO, AGA medical corporation, Plymouth, 
MN, USA) in symptomatic small children.8) However, anoth-
er recent report states that device closure is a safer and more 
effective alternative to surgery, with valid advantages in very 
small children, including infants and those who weigh less 
than 10 kg.9-12) Cardenas et al.10) reported that there was no 
additional risk in smaller babies (<10 kg) for transcatheter 
ASD closure, and also in our study comparing outcomes of 
device therapy to those of surgical closure in small children 
with 10 kg of weight or less, the superior safety of the device gr-
oup was evident, which was proved by a lower complication 
rate.11)
 
Problems in transcatheter atrial septal defect 
closure in small children
There are several problems encountered during device clo-
sure in small children. The vessels are relatively small compar-
ed to the large delivery system, which leaves the possibility for 
potential damage to vascular access. Moreover, because of the 
rigid coupling mechanism between the device and delivery 
cable as well as the relatively stiff delivery system, there is a la-
tent risk for damage to the cardiac tissue. The inherent design 
of ASO with the relatively-excessive rim width of atrial discs 
in smaller devices (Fig. 1) may also increase the potential risk 
for erosion or cessation of the procedure, because the exces-
sive atrial rims may encroach on the adjacent cardiac struc-
tures or atrioventricular valves. Because of the small total 
septal length in small hearts, plans for implantation of large 
devices may occasionally be thwarted, especially in small ch-
ildren with relative mitral rim deficiency. Therefore, in order 
to ensure procedural safety, special care must be taken to pre-
vent damage to the vasculature and to cardiac structures, and 
the procedure should be conducted by an experienced hand 
in this subset of the patient population. Also, further modi-
fications of the design for smaller sizes of the device to fit a 
small heart may be needed to increase the applicability of the 
procedure to smaller children. On the other hand, a “stopgap 
technique”, which is choosing the device size according to the 
size of the heart so the left atrial disc diameter can fit the ma-
ximal septal length has been suggested.13) This technique may 
be a good solution for small children with a relatively large de-
fect diameter to total septal length ratio, but the interpretation 
for the usefulness of this technique still requires further in-
vestigation. 
Transcatheter Closure of Atrial Septal 
Defect in Elderly Patients
Pathophysiology of untreated atrial septal defect 
in the elderly
Elderly patients with hemodynamically significant ASD 
frequently experience complications with serious long-term 
adverse consequences such as pulmonary hypertension, atrial 
arrhythmia, and atrioventricular valve insufficiencies that es-
sentially involve the tricuspid valve as well as right-sided heart 
A  B  
32 mm ASO 12 mm ASO
Fig. 1. Discrepancy in the left atrial disc and waist ratio (a/b). This 
figure shows that in 32 mm ASO, the (a) and (b) ratio is 1.44, but in 
a 12 mm ASO, the (a) and (b) ratio is 2.17. Relative large rim of LA 
disc in smaller devices may encroach to adjacent cardiac structures 
which prevent safe device closure. In reality, these are entirely dif-
ferent devices, when considering the structure and shape. There-
fore, the discrepancy maximizes as the device gets smaller. LA disc 
is marked. a: left atrial disc, b: waist of device. A: anterior-posterior 
view of 32 mm ASO demonstrates the relationship of left atrial 
disc and waist size. B: anterior-posterior view of 12 mm ASO re-
veals that left atrial disc occupies large area in smaller device. 
ASO: Amplatzer septal occluder.
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failure secondary to chronic volume overload of the right 
side of the heart.14) This group of patients has a higher preval-
ence of co-morbid cardiovascular and/or systemic diseases in-
cluding systemic hypertension, stroke, chronic lung disease, 
diabetes mellitus, atherosclerosis and coronary heart dis-
ease.14-16) The pathophysiologic mechanism is summarized in 
Fig. 2. Longstanding left to right shunt in the atrial level re-
sults in progressive right heart dilatation, significant tricuspid 
insufficiency and subsequent increase in right atrial pressure. 
Left heart may also be influenced by chronic volume under-
load, increased atrial pressure as well as co-morbid diseases 
such as systemic hypertension or coronary heart disease. Sig-
nificant numbers of the patients are also affected by more ad-
vanced complications inherent to the end stage of this patho-
physiologic cascade, including pulmonary hypertension, ven-
tricular dysfunction and atrial arrhythmias which cause signi-
ficant symptoms. In addition, diastolic compression of left ven-
tricle (LV) by dilated right ventricle reduces LV end-diastolic 
volume in chronic setting, and this is responsible for so called 
“masked LV restriction” which may cause serious pulmonary 
edema secondary to LV dysfunction and left atrium (LA) pres-
sure increase after ASD closure.17) Because of the chronic na-
ture of the disease, patients are usually adapted to the disabili-
ties they have had and invasive interventions are occasionally 
refused by patients. Nevertheless, scarce evidence for surviv-
al benefit of anatomical closure and higher potential risk of 
definitive treatment in this group of patients may sometimes 
affect the decision to a more conservative one. 
Outcomes of atrial septal defect closure in elderly 
population
The benefits from ASD closure in the elderly population 
has been documented in fewer reports compared to the youn-
ger population. In the 1990s, there was a nonrandomized st-
udy debating the clinical benefits between medical treatment 
only and anatomical closure.18) However, a relatively recent 
randomized study in a large population confirmed that ana-
tomical closure is superior to medical treatment in prevent-
ing major events.19) Moreover, the realistic benefits of ASD clo-
sure include symptomatic relief, improvements of functional 
status as well as the quality of life.20)21) These favorable clinical 
changes are supported by the immediate and substantial re-
verse remodeling of the heart after closure from many stud-
ies.14)16)17)22) Excellent safety and efficacy in terms of improv-
ing functional class and favorable reverse remodeling of the 
heart have been consistently reported, and the solutions for 
major complications such as restrictive LV, chronic atrial ar-
rhythmia and pulmonary hypertension have been discussed 
as major issues.
Problems in transcatheter atrial septal defect 
closure in elderly patients
The most important problem in elderly patients is that they 
have more complex presentations of the disease, mainly be-
cause they frequently have co-morbid systemic and heart dis-
eases as previously mentioned. This necessitates precise evalu-
ation of the risk factors as an essential part of successful treat-
ment. Co-morbid diseases in elderly patients in recent public-
ations are shown on Table 1.14-16) More than one third of the 
patients showed systemic hypertension and systemic diseases 
such as diabetes mellitus, and a considerable extent of pulmo-
nary and neurological diseases were also present.
Cardiac co-morbidities include pulmonary hypertension 
in nearly half of the patients, chronic atrial arrhythmia in 
more than 20% and ischemic heart disease in about 15% of 
the patients. Post-closure pulmonary edema caused by “ma-
sked LV restriction” may appear in 2 to 4% of the elderly pa-
tients and should be ruled out before ASD closure through a 
balloon occlusion test. It was previously described that most 
of the patients with evidence of LV restriction during tempo-
Longstanding Lt-Rt shunt in atrial level
RAE/RVE
Increase Lt-Rt shunt
Progressive RAE/RVE
CO ↓, LV restriction
RV/LV failure
LV volume ↓
PAH
TR ↑ RAP ↑
LAP  ↑, LAE A Fib/A Flut
HTN, IHD
Symptom
Fig. 2. The pathophysiologic mechanisms in elderly patients with atrial septal defect. Longstanding left to right shunt in the atrial level re-
sults in progressive right heart dilatation, significant TR and subsequent increase in RA pressure. Left heart may also be influenced by 
chronic volume underload, increased atrial pressure as well as co-morbid diseases. Lt: left, Rt: right, RAE: right atrial enlargement, RVE: 
right ventricular enlargement, LV: left ventricle, HTN: hypertension, IHD: ischemic heart disease, CO: cardiac output, PAH: pulmonary arte-
rial hypertension, TR: tricuspid regurgitation, RAP: right atrial pressure, LAP: left atrial pressure, LAE: left atrial enlargement, A Fib: atrial fi-
brillation, A Flut: atrial flutter.
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rary balloon occlusion of the defect may show favorable resp-
onse to several days of anti-congestive therapy, so that they 
could go through with the device closure without any seri-
ous events.
Even though LV dysfunction after ASD closure is not a fre-
quent finding, it may lead to a serious consequence once it 
occurs. Thus, the detection of the risk for serious LV restric-
tion before the procedure is very important. There are 2 dif-
ferent protocols for detection and management of high risk 
patients, which have been independently developed by 2 se-
parate groups (Fig. 3).5)14)15)17)23) Both protocols involve a tem-
porary balloon occlusion test and measurement of LA pres-
sure, but the definition of significant LV restriction is quite dif-
ferent for each protocol. Both protocols recommend several 
days of medical therapy including diuretics, inotropic agents 
and afterload reducing therapy once LV restriction is diagnos-
ed, and if the patient proves to be refractory to medical thera-
py on a subsequent balloon occlusion test, they are recomme-
nded a fenestrated device (Fig. 4). These protocols were be-
lieved to be useful in the therapeutic approach to high-risk 
patients, but both protocols are based on empirical experienc-
es rather than cumulated data which raises doubt on the re-
liability of each numerical criterion that they have suggested.
Previous studies identified several risk factors for persistent 
atrial arrhythmias, such as pulmonary hypertension, valvular 
dysfunction with atrial enlargement, presence of atrial arrhy-
thmia before closure of ASD, and not surprisingly, all these 
factors are commonly linked to the most important risk fac-
tor, the age of the patient.24-26) Therefore, it is very important 
to close a hemodynamically significant defect early before 
cascade of deleterious events begin.
In elderly ASD patients with permanent atrial fibrillation, 
Table 1. Incidence of co-morbid cardiac and systemic diseases among elderly patients over 60 years of age
Schubert15) (Berlin, 59 patients) Swan16) (Toronto, 50 patients) Spies14) (Chcago, 55 patients)
Systemic disease
Hypertension (%) 42.4 34 -
DM (%) - 06 -
Lung disease (%) - 04 -
Cerebral insult (%) 13.6 - -
Cardiac comorbidity 
Pulm hypertension (%) 49 - 42
A Fib +/- A Flut (%) 40 20 24
Coronary HD (%) 13.6 16 -
LV dysfunction (%) - 08 -
or LV restriction (%) 25 - -
Pulm edema (%) - 02 -
or fenestrated device (%) 3.4 - 3.6
DM: diabetis mellitus, pulm: pulmonary, A Fib: atrial fibrillation, A Flut: atrial flutter, HD: heart disease, LV: left ventricle
Elderly ASD
Mean LAP >5 (or 18) mm Hg
Adult ASD with Risk
(Elderly)
Balloon occlusion; 15 minutes
Increase of mean LAP >5 mm Hg
Balloon occlusion; 10 minutes
Mean LAP >10 mm Hg
Conditioning therapy
Aterload reducing agent+diuretics 
for days - weeks
Routine
device
closure
Conditioning therapy
IV inotropics+diuretics
for 48 - 60 hours
Balloon occlusion; 15 minutes
Increase of mean LAP >5 mm Hg
Balloon occlusion; 10 minutes
Mean LAP >10 mm Hg
Fenestrated device Fenestrated device
YesYes
No
No
No
No
YesYes
Fig. 3. Different protocols for the detection and management of high risk patients. If left ventricle restriction is detected, both protocols rec-
ommend several days of medical therapy including diuretics, inotropic agents and afterload reducing therapy, and if the patient is refractory 
to medical therapy on a subsequent balloon occlusion test, they recommend using a fenestrated device.5)14)15)23) LAP: left atrial pressure, 
ASD: atrial septal defect. 
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there are 2 therapeutic options which include rhythm control 
and rate control. Rhythm control involves surgical correction 
of ASD with Maze procedure at the time of operation, or de-
vice closure with catheter ablation. Rate control is achieved by 
medical treatment including anticoagulation and occasional 
antiarrhythmic drugs according to the baseline heart rate or 
arrhythmic event after closure of the defect. A rhythm control 
policy may be the preferable option in patients with sympto-
matic tachyarrhythmia. 
A recent study on elderly patients with ASD and chronic at-
rial fibrillation, reported that the outcome of device closure 
was as good as the outcome from patients without atrial fibril-
lation in terms of safety, improvement of functional status and 
reverse remodeling of the heart.27) Their strategy was based on 
the previous study comparing rhythm control and rate con-
trol, which revealed that there was no difference in mortality 
and quality of life between these strategies (AFFIRM study).28) 
However, this subject may be controversial since for the time 
being, the predominant opinion is that rhythm control ap-
pears to be superior to rate control in the treatment of atrial 
fibrillation.29) 
Conclusion
For small children, a more sophisticated technical approach 
and decision making is needed, keeping in mind that the clo-
sure system is not specifically designed for the small heart and 
vessels of very young children. To promote the applicability 
of device closure, further modification of the device towards 
decreased rim to waist diameter ratio is warranted. 
For elderly patients, thorough evaluation of co-morbidities 
and risk factors is important to predict post-procedural com-
plication. The physician must let their patients know about 
the serious complications such as chronic atrial arrhythmia 
and PAH which may persist after ASD closure so that they 
can make the right decision in choosing the treatment moda-
lity as well as promote compliance to further medical treat-
ment. Also, even though LV dysfunction (LV restriction) after 
device closure is not frequent, special care must be taken in 
high risk patients because potentially serious outcomes may 
be prevented by fastidious evaluation and appropriate treat-
ment plan.
In conclusion, transcatheter closure of secundum ASD with 
the ASO is technically feasible, safe and effective for many age 
groups. A meticulous approach and individualized strategy 
for each patient are mandatory to maximize the efficacy and 
safety of this versatile therapy.
REFERENCES
1) Park MK. Pediatric Cardiology for Practitioners. 5th ed. Philadelphia: 
Mosby Elsevier;2008. p.161-91.
2) Bull C, Deanfield J, de Leval M, Stark J, Taylor JF, Macartney FJ. Cor-
rection of isolated secundum atrial septal defect in infancy. Arch Dis 
Child 1981;56:784-6.
3) Lammers A, Hager A, Eicken A, Lange R, Hauser M, Hess J. Need for 
closure of secundum atrial septal defect in infancy. J Thorac Cardio-
vasc Surg 2005;129:1353-7.
4) Hijazi ZM, Celiker A. Closure of atrial septal defects. Anadolu Kardi-
yol Derg 2005;5:331.
5) Holzer R, Hijazi ZM. Interventional approach to congenital heart dis-
ease. Curr Opin Cardiol 2004;19:84-90.
6) Keane JF, Lock JE, Fyler DC. Nadas’ Pediatric Cardiology. 2nd ed. 
Philadelphia: Saunders Elsevier;2006. p.603-16.
7) McMahon CJ, Feltes TF, Fraley JK, et al. Natural history of growth of 
secundum atrial septal defects and implications for transcatheter clo-
sure. Heart 2002;87:256-9.
8) Vogel M, Berger F, Dähnert I, Ewert P, Lange PE. Treatment of atrial 
septal defects in symptomatic children aged less than 2 years of age us-
ing the Amplatzer septal occluder. Cardiol Young 2000;10:534-7.
9) Diab KA, Cao QL, Bacha EA, Hijazi ZM. Device closure of atrial sep-
tal defects with the Amplatzer septal occluder: safety and outcome in in-
fants. J Thorac Cardiovasc Surg 2007;134:960-6.
10)  Cardenas L, Panzer J, Boshoff D, Malekzadeh Milani S, Ovaert C. 
Transcatheter closure of secundum atrial defect in small children. Ca-
theter Cardiovasc Interv 2007;69:447-52.
11) Choi JY, Kim NK, Park SJ, Park HK, Park YH, Sul JH. Feasibility 
and safety of Transcatheter closure of atrial septal defect in small child-
ren weighing 10kg or less. Catheter Cardiovasc Interv 2008;1:S10. Ab-
stract.
12) Wood AM, Holzer RJ, Texter KM, et al. Transcatheter elimination of 
left-to-right shunts in infants with bronchopulmonary dysplasia is fea-
sible and safe. Congenit Heart Dis 2011;6:330-7.
13) Amin Z. Transcatheter closure of secundum atrial septal defects. Ca-
theter Cardiovasc Interv 2006;68:778-87.
14) Spies C, Hijazi ZM. Transcatheter Closure of Secundum Atrial Septal 
Defects in the Elderly. Korean Circ J 2009;39:47-51.
15) Schubert S, Peters B, Abdul-Khaliq H, Nagdyman N, Lange PE, Ew-
ert P. Left ventricular conditioning in the elderly patient to prevent 
congestive heart failure after transcatheter closure of atrial septal de-
fect. Catheter Cardiovasc Interv 2005;64:333-7.
16) Swan L, Varma C, Yip J, et al. Transcatheter device closure of atrial 
septal defects in the elderly: technical considerations and short-term 
Fig. 4. Self-fabricated fenestrated device. Fabrication of the device 
by creating fenestration (white arrow) in both discs and connect-
ing waist can be achieved using various sized dilators. Ties using 
non-absorbable suture materials (black arrow head) ensures the 
maintenance of fenestration.
638   Transcatheter Closure of ASD: Does Age Matter?
outcomes. Int J Cardiol 2006;107:207-10.
17) Elshershari H, Cao QL, Hijazi ZM. Transcatheter device closure of 
atrial septal defects in patients older than 60 years of age: immediate 
and follow-up results. J Invasive Cardiol 2008;20:173-6.
18) Shah D, Azhar M, Oakley CM, Cleland JG, Nihoyannopoulos P. Na-
tural history of secundum atrial septal defect in adults after medical or 
surgical treatment: a historical prospective study. Br Heart J 1994; 
71:224-7.
19) Attie F, Rosas M, Granados N, Zabal C, Buendía A, Calderón J. Surgi-
cal treatment for secundum atrial septal defects in patients >40 years 
old: a randomized clinical trial. J Am Coll Cardiol 2001;38:2035-42.
20) Miyaji K, Furuse A, Tanaka O, Kubota H, Ono M, Kawauchi M. Sur-
gical repair for atrial septal defect in patients over 70 years of age. Jpn 
Heart J 1997;38:677-84.
21) Shibata Y, Abe T, Kuribayashi R, et al. Surgical treatment of isolated 
secundum atrial septal defect in patients more than 50 years old. Ann 
Thorac Surg 1996;62:1096-9.
22) Yalonetsky S, Lorber A. Comparative changes of pulmonary artery 
pressure values and tricuspid valve regurgitation following transcath-
eter atrial septal defect closure in adults and the elderly. Congenit Heart 
Dis 2009;4:17-20.
23) Ewert P, Berger F, Nagdyman N, et al. Masked left ventricular restric-
tion in elderly patients with atrial septal defects: a contraindication for 
closure? Catheter Cardiovasc Interv 2001;52:177-80.
24) Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial ar-
rhythmia after surgical closure of atrial septal defects in adults. N Engl 
J Med 1999;340:839-46.
25) Oliver JM, Gallego P, Gonzlez A, Benito F, Mesa JM, Sobrino JA. 
Predisposing conditions for atrial fibrillation in atrial septal defect with 
and without operative closure. Am J Cardiol 2002;89:39-43.
26) Silversides CK, Siu SC, McLaughlin PR, et al. Symptomatic atrial ar-
rhythmias and transcatheter closure of atrial septal defects in adult 
patients. Heart 2004;90:1194-8.
27) Taniguchi M, Akagi T, Ohtsuki S, et al. Transcatheter closure of atrial 
septal defect in elderly patients with permanent atrial fibrillation. Ca-
theter Cardiovasc Interv 2009;73:682-6.
28) Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control 
and rhythm control in patients with atrial fibrillation. N Engl J Med 
2002;347:1825-33.
29) Verma A, Natale A. Should atrial fibrillation ablation be considered 
first-line therapy for some patients? Why atrial fibrillation ablation sh-
ould be considered first-line therapy for some patients. Circulation 
2005;112:1214-22.
